FDA’s updated RWE guidelines allow pharma marketers to make more claims

Prevailing regulations state that only “on-label” claims may be used by manufacturers in pharma advertising.

A draft guidance released this week by the Food and Drug Administration, provides an alternate regulatory pathway for the approved label to have the most up-to-date information — including for how marketers can make subsequent product claims.